TPTX:NSD-Turning Point Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 33.26

Change

-3.43 (-9.35)%

Market Cap

USD 1.82B

Volume

0.81M

Avg Analyst Target

USD 92.25 (+177.36%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Turning Point Therapeutics Inc (TPTX) Stock Analysis:
Based on the Turning Point Therapeutics Inc stock forecasts from 9 analysts, the average analyst target price for Turning Point Therapeutics Inc is USD 92.25 over the next 12 months. Turning Point Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Turning Point Therapeutics Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Turning Point Therapeutics Inc’s stock price was USD 33.26. Turning Point Therapeutics Inc’s stock price has changed by -7.84% over the past week, +8.69% over the past month and -52.89% over the last year.

About

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GILD Gilead Sciences Inc

+0.69 (+1.08%)

USD80.08B 17.83 11.21
REGN Regeneron Pharmaceuticals Inc

+4.11 (+0.60%)

USD72.62B 9.40 7.18
VRTX Vertex Pharmaceuticals Incorpo..

+0.13 (+0.05%)

USD66.14B 27.29 19.22
MRNA Moderna Inc

-5.56 (-4.04%)

USD54.19B 4.01 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-8.72 (-5.34%)

USD39.61B 3.12 1.86
RPRX Royalty Pharma plc

-0.31 (-0.77%)

USD26.64B 28.87 15.23
SGEN Seagen Inc

-5.87 (-4.21%)

USD25.70B 55.02 44.86
GMAB Genmab A/S

-0.30 (-0.97%)

USD20.43B 60.76 5.35
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing TPTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.27% 74% C 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.27% 74% C 41% F
Trailing 12 Months  
Capital Gain -51.70% 64% D 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.70% 64% D 31% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.60% 67% D+ 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.60% 67% D+ 75% C
Risk Return Profile  
Volatility (Standard Deviation) 65.30% 43% F 22% F
Risk Adjusted Return 31.55% 70% C- 59% F
Market Capitalization 1.82B 90% A- 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.97 46% F 43% F
Price / Cash Flow Ratio -11.86 85% B 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -27.65% 80% B- 32% F
Return on Invested Capital -23.06% 80% B- 31% F
Return on Assets -16.07% 77% C+ 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.99 50% F 33% F
Short Percent 7.56% 32% F 23% F
Beta 0.84 76% C 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.